A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

MLA

Weickhardt A, et al. “A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 7, no. 2, Feb. 2012, pp. 419–26. EBSCOhost, https://doi.org/10.1097/JTO.0b013e31823c5b11.

APA

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Camidge DR, Weickhardt, A., & Doebele, R. (2012). A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 7(2), 419–426. https://doi.org/10.1097/JTO.0b013e31823c5b11

Chicago

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, et al. 2012. “A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology 7 (2): 419–26. doi:10.1097/JTO.0b013e31823c5b11.